IEQ Capital’s AbCellera Biologics ABCL Stock Holding History

IEQ Capital’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-245,963	Closed	-$841K	–	1882
2025 Q4	$841K	Hold	245,963	–	–	﹤0.01%	1108
2025 Q3	$1.24M	Buy	+245,963	New	+$1.08M	﹤0.01%	930

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

IEQ Capital's ABCL Position: Q1 2026 in Review

IEQ Capital sold out of AbCellera Biologics (ABCL) in Q1 2026, closing a stake of 245,963 shares — an estimated $841K sold.

IEQ Capital first reported a position in ABCL in Q3 2025 and held it in 2 quarters. The position peaked at $1.24M in Q3 2025. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

IEQ Capital reported no remaining AbCellera Biologics position as of Q1 2026 after selling out during the quarter.
IEQ Capital sold 245,963 AbCellera Biologics shares in Q1 2026, an estimated $841K.
IEQ Capital first reported a position in AbCellera Biologics in Q3 2025 and held it in 2 quarters.
IEQ Capital's AbCellera Biologics position peaked at $1.24M in Q3 2025.
138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on IEQ Capital's 13F filing for Q1 2026, filed 15 May 2026.